HomeTrialNCT06636383
🔬NCT06636383RECRUITING

Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program

Study Summary

The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment140 participants
Primary Completion
Lead SponsorUltragenyx Pharmaceutical Inc
Data Retrieved2026-04-11 04:25:35.045769+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.